Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up The Treatment Algorithm - Biologics Market Research

Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up The Treatment Algorithm
Published Date: September 2006
Published By: Datamonitor
Page Count: 181
Order Code: R313-16760
Price: $15,200 Online Download
$30,400 Global Site License
Introduction
Rheumatoid arthritis is a debilitating and life-long disease that is estimated to affect approximately 5 million people in the seven major markets. The launch of anti-TNF products over six years ago and more recent novel target biologic therapies have added significantly to the treatment options, but have resulted in a crowded market for moderate to severe patients.
Scope of this report
Disease overview including epidemiology, physician estimated diagnosis rates and severity split, including mild to severe and early active disease
Breakdown of treatment trends in the following markets: US, Japan, France, Germany, Italy, Spain and the UK
PCPs and rheumatologists surveyed to capture the treatment of the ranging severities with traditional NSAIDs, COX-2s, traditional and biologic DMARDs
Comparative brand assessment on the key attributes of Enbrel, Remicade, Humira, Orencia, Rituxan/MabThera, Kineret and methotrexate
Research and analysis highlights
Inclusion of relevant early active RA patients in clinical studies will assist timely approval in this indication, increasing the patient base for any RA product. Definition of 'early' RA requires a balance between the physician ideal of less than 12 months, giving the best patient response, and capturing a substantial proportion of the market.
Physicians estimate nine months from disease onset to diagnosis. 25% of RA patients are estimated to be severe, and take an average of four months before the first DMARD is prescribed, being methotrexate in 60% of physicians. It can be 18-23 months before a severe patient is likely to use a biologic.
Anti-TNF therapy is expected to continue to dominate the first-line biologic use. Humira is perceived to be the most effective in terms of disease modification, indicating a very positive future status for this brand, but Remicade and Kineret could lose the brand battle if perception on certain attributes doesn't improve.
Key reasons to read this report
Use estimated treatment class patient numbers to forecast product use across the seven major markets
Exploit physician perceptions of key brands on clinical and market attributes, to differentiate products in the crowded rheumatoid arthritis market
Understand differential treatment in niche populations such as severe and early active rheumatoid arthritis